This observational study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe rheumatoid arthritis. Data will be collected from patients for the 12 months following the first infusion of RoActemra/Actemra.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01394276?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
